Phospholipids (Essentiale Forte P) advocates for the recognition of everyday liver care as a central issue for our vitality. Through supporting the liver on a regular basis, we can seize every day with vigor and regain the energy sourced by the liver.
We actively engage consumers and healthcare professionals (HCPs) in our quest to give liver care the attention it deserves through constant and passionate education.
Start caring about your liver with Phospholipids (Essentiale Forte P) today. Help us build a liver care culture that will remind everyone than you can only call your lifestyle healthy if you treat your liver right.
Suffering liver is sometimes silent, but Phospholipids (Essentiale Forte P) improvement effect is visible in the liver proven by ultrasound results1. Phospholipids (Essentiale Forte P) has a solid clinical proof in the following indications:
Non-Alcoholic Fatty Liver Disease
Chronic Viral Hepatitis
Alcoholic Liver Disease
Regenerates naturally damaged liver cells
Strengthens the liver and its effects on vital body functions
Protects the body from toxins
Phospholipids (Essentiale Forte P) a liver care medication that contains high concentration of purified essential phospholipids (EPLs) which facilitate the regeneration of damaged liver cells.
Phospholipids (Essentiale Forte P)'s history began 100 years ago in Cologne, Germany; marketed since 1987. Over the past few decades, the areas of research, development and testing have remained a priority for the company. Phospholipids (Essentiale Forte P) is owned by Sanofi - the leading French multinational pharmaceutical company.
Today, Phospholipids (Essentiale Forte P) is the global market leader among over-the-counter (OTC) liver therapies, supported by over 50 years of experience in EPLs and liver care.
From its modest beginnings in Germany, Phospholipids (Essentiale Forte P) has established itself as a top global player in the Digestive Health market. The company has developed a global presence that now spans a wide array of regions - Europe, Asia, the Middle East and Latin America.
More than 8 out of 10 doctors and consumers were satisfied with Phospholipids (Essentiale Forte P)'s treatment11.
Generally, experience with the use of Phospholipids (Essentiale Forte P) is good or very good for 100% of patients, and 96% of patients reported good or very good satisfaction with the relief of symptoms for which they took Phospholipids (Essentiale Forte P)12.
Yin D, Kong L. Observation for curative effect of Essentiale in treatment of fatty liver caused by diabetes mellitus. Med J Q Ilu.2000;15:277–278.
Demirbilek S, Karaman A, Gürünlüoğlu K, et al. polyenyl phosphatidylcholine pre-treatment protects rat liver from ischemia/ reperfusion injury. Hepatol Res. 2006;34:84-91.
Martelli A, Mereto E, Ghia M. Protective effect of phosphatidylcholine on hepatic lipid peroxidation in rats. Med Sci Res.1989;17:995-996.
Gunderman K-J, Kuenker A, Kuntz E et al. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol Rep. 2011;63:643-659.
Dajani AIM, Abu Hammour AM, Zakaria MA, et al. Essential phospholipids as a supportive adjunct in the management of patients with NAFLD. Arab Journal of Gastroenterology. 2015;16:99-104.
Maev, Igor V.; Pavlov, Chavdar S. Essentiale®: Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: a real-life observational study from Russia. BMJ Open Gastroenterology 2019; Doi: 10.1136/bmjgast-2019-000368
Buyeverov AO, Yeshanu VS, Mayevskaya MV, et al. Application of essential phospholipids in complex therapy of steatohepatitis of the mixed origin. Klin Persp Gastroenterol Hepatol.2008;1:17–22. Russian
Gunderman KJ et al. Pharmacol Rep 2011;63:643-669
Gunderman KJ et al. Clin Exper Gastroenterol. 2016;9:105-117
Maev, Igor V.; Pavlov, Chavdar S. Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive therapy in Russia. BMJ Open Gastroenterology 2019; Doi: 10.1136/bmjgast-2019-000307
PEX_Sanofi Essentiale - Study with Patients - Market Research Report. PexPharmaSequence. May, 2020.